Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>/=18 years of age~* histologically confirmed metastatic melanoma (Stage IV, AJCC)~* patients must have completed and failed at least one prior standard of care regimen (e.g. DTIC, temozolomide, etc.)~* BRAF V600E positive mutation (by Roche CoDx BRAF mutation assay)~* measurable disease by RECIST criteria~* negative pregnancy test and, for fertile men and women, effective contraception during treatment and for 6 months after completion~Exclusion Criteria:~* active CNS metastases on CT/MRI within 28 days prior to enrollment~* history of or known carcinomatous meningitis~* previous treatment with BRAF (sorafenib allowed) or MEK inhibitor~* cardiac dysrhythmias \>2 NCI CTCAE or treatment with drugs with dysrhythmic potential~* uncontrolled hypertension(\>150/100mmHg) despite optimal medical therapy~* infectious disease including HIV, HBV and HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).